Item 8.01 Other Events.
On June 16, 2021, Blueprint Medicines Corporation (the "Company") issued a press
release announcing that the U.S. Food and Drug Administration ("FDA") approved
the Company's supplemental new drug application for AYVAKIT™ (avapritinib) for
the treatment of adult patients with advanced systemic mastocytosis, including
patients with aggressive systemic mastocytosis, systemic mastocytosis with an
associated hematological neoplasm, and mast cell leukemia. A copy of the press
release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press release issued by Blueprint Medicines Corporation
on June 16, 2021
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document and incorporated as Exhibit 101)
© Edgar Online, source Glimpses